Goldman Sachs Asks: 'Is Curing Patients a Sustainable Business Model?' (cnbc.com)
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." From a report: "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote.
Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote.
"Slashdot asks: Is posting fresh stories a sustainable business model?"
Ezekiel 23:20
Time to blacklist anyone working at goldman sachs from getting any sort of cure.
Curing something does not mean you won't sell the same cure to the same person again. Just because you cured HepC, hell, even curing AIDS in a person does not mean they can't get infected again and need your cure again.
The number of diseases that grant lifetime immunity to it after you survived it once is fairly low.
We used to have a Bill of Rights. Now, with the rights gone, all we have left is the bill.
If your competitors can't. If you develop a treatment and your competitor has a cure then your business is flushed down the toilet while your competitor gets rich. So unless the biotech companies collude with each other there is always the risk that a competitor will produce a cure killing your business, so you had better get there first and kill their business instead.
Yes, bloody idiots.
The longer the person lives the longer he might be a client of various medical/pharmaceutical companies because we're not getting younger and healthier with each passing day.
The main problem is looking at health care as a profit driven business in the first place. Take a look at Europe / Scandinavia for examples of much better models.
There are two choices, and they have their detractors:
1. Socialism: We all pay for this and enjoy the benefits of a healthy society.
2. Ferengi: Mortgage. Because the treatment works so well, it is also expensive, and the only way to finance it is by taking a lifetime loan. If you need a second treatment, better take a second mortgage then.
"Everybody's naked underneath" -- The Doctor
As opposed to the rest of the 1st world countries which manage to have affordable and working health care systems. Canada, France, UK etc all have single payer systems with working hospitals and better health outcomes at a fraction of the price.
Computer modeling for biotech drug manufacturing is HARD!
No, it's actually about high time somebody asked this question.
I've recently been thinking about this a little in terms of game theory: Insurance companies see medical care as an expense and premiums as income. Patients see medical care as a benefit and insurance premiums as an expense. This has led to a system with a whole lot of problems, but the fundamental flaw is that the two sides have fundamentally conflicting goals.
How can we rework this into a better system?
The first thing we need to do is define the goal of the system, and "longer average lifespan" seems like the right goal. We can also add a quality of life rider by saying that anyone can check out if their life becomes unbearable, with lots of safeguards against coercion and suicidal depression and such. (I imagine a process similar to sex-change operations - the patient has to really want it over an extended time, and have psychiatrist buy-in.)
With "longer average lifespan" as the goal, now how do we pay the doctors?
One answer might be to assign to the *doctor* (primary care physician) a monthly fee per patient, regardless of that patient needing medical service. If patients could switch to a new doctor at any time and for any reason, doctors would then have incentive to a) provide the best medical care, b) compete with each other for quality of service, and c) keep their patients healthy, happy, and long-lived.
This seems to work at the "primary care physician" level, but it isn't a good fit for specialist and above, hospital care and ER. The PCP should feel free to refer a patient to a specialist without incurring a drop in salary, and an ER doc should have incentive to save a patient's life without regard to payment.
Also, medical research should be included, so that there's incentive to cure diseases instead of masking symptoms.
Anyone good at game theory like to add to this model?
Drillem, Billum, Killem and Chillum. Seriously, there is a whole class of human endeavor that is not made better by the profit motive. Healthcare certainly belongs in it. It is something that should be pursued by practitioners and institutions to improve the public good not to get filthy rich. Charging large sums of money to prolong life is essentially extortion. Most developed societies recognize this by having long ago instituted single-payer systems. It is expensive, but demonstrably such a system vastly improves the society's productivity and quality of life from the bottom up -- a measurable plus economically. And, besides, it is just the decent way to run things.
"No fear. No envy. No meanness." Liam Clancy
"Cancer survival rates" are a baloney statistic. What matters are mortality rates. If I diagnose a cancer earlier and the treatment does exactly nothing, my survival rate improves while the mortality rate stays the same. In fact, if I can diagnose false positives, my survival rate looks even better while mortality stays constant. The more harmless lumps I remove from the breasts of healthy women, the better and better my survival statistics look.
Measured by mortality rate the US is not substantially better or worse than any other rich industrial nation, including the UK. It is a myth that the US system is better at all.
That is basically the ancient Chinese model. Everyone living in the same lock with the doctor payed a monthly fee.
Got he sick, he stopped paying and visited the doctor. As soon as he was cured, he payed again.
I'm not sure this would work under game theory, because people would have an incentive to get out of paying by claiming to be sick when they're not, or get out of paying by going to the doctor for trivial reasons.
For the system to work, there can't be any monetary incentive to "game" the system. The system has to be viewed from all angles, and cheating and other abuses have to be eliminated from the point of view of incentive.